Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Type
Type
Guidance (67)
Guidance programme
Guidance programme
Health technology evaluations (3)
Technology appraisal guidance (64)
Apply filters
Showing 11 to 20 of 67
Keyword or reference number: cancer
Remove Keyword or reference number: cancer filter
Guidance and quality standards awaiting development
Title
Type
Ceralasertib with durvalumab for treating advanced non-small-cell lung
cancer
after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]
Technology appraisal guidance
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung
cancer
after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung
cancer
without actionable genomic alterations [ID6522]
Technology appraisal guidance
Datopotamab deruxtecan with durvalumab for treating triple-negative breast
cancer
when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]
Technology appraisal guidance
Digital AI tools in histopathology (breast and prostate
cancer
)
Health technology evaluation
Dorocubicel for treating haematological
cancer
when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]
Technology appraisal guidance
Dostarlimab for treating primary advanced or recurrent endometrial
cancer
with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]
Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal
cancer
before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder
cancer
after resection of papillary tumours in people previously untreated with BCG [ID5080]
Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder
cancer
when cisplatin is unsuitable [ID6445]
Technology appraisal guidance
Previous page
1
Current page
2
3
4
…
7
Page
2
of
7
Next page
Results per page
10
25
50
All
Back to top